scholarly journals Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5938
Author(s):  
Javier Torres-Jiménez ◽  
Jorge Esteban-Villarrubia ◽  
Reyes Ferreiro-Monteagudo ◽  
Alfredo Carrato
Keyword(s):  
Colorectal Cancer ◽  
Cancer Metastasis ◽  
Routine Clinical Practice ◽  
Point Of View ◽  
Medical Oncologist ◽  
Internal Radiation ◽  
Hepatic Parenchyma ◽  
Colorectal Cancer Metastasis ◽  
Interventional Therapies ◽  
Isolated Liver

For patients with isolated liver metastases from colorectal cancer who are not candidates for potentially curative resections, non-surgical local treatments may be useful. Non-surgical local treatments are classified according to how the treatment is administered. Local treatments are applied directly on hepatic parenchyma, such as radiofrequency, microwave hyperthermia and cryotherapy. Locoregional therapies are delivered through the hepatic artery, such as chemoinfusion, chemoembolization or selective internal radiation with Yttrium 90 radioembolization. The purpose of this review is to describe the different interventional therapies that are available for these patients in routine clinical practice, the most important clinical trials that have tried to demonstrate the effectiveness of each therapy and recommendations from principal medical oncologic societies.

Fusobacterium nucleatum Promotes Colorectal Cancer Metastasis by Modulating KRT7-AS/KRT7

2019 ◽  
Author(s):  
Shujie Chen ◽  
Tingting Su ◽  
Ying Zhang ◽  
Allen Lee ◽  
Jiamin He ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Metastasis ◽  
Fusobacterium Nucleatum ◽  
Colorectal Cancer Metastasis

scholarly journals IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Chenyang Qiao ◽  
Wenjie Huang ◽  
Jie Chen ◽  
Weibo Feng ◽  
Tongyue Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Cancer Metastasis ◽  
Combined Treatment ◽  
Insulin Like Growth Factor ◽  
Atp Citrate Lyase ◽  
Citrate Lyase ◽  
Elevated Expression ◽  
Igf1r Inhibitor ◽  
Colorectal Cancer Metastasis

AbstractMetastasis is the major reason for the high mortality of colorectal cancer (CRC) patients and its molecular mechanism remains unclear. Here, we report a novel role of Homeobox A13 (HOXA13), a member of the Homeobox (HOX) family, in promoting CRC metastasis. The elevated expression of HOXA13 was positively correlated with distant metastasis, higher AJCC stage, and poor prognosis in two independent CRC cohorts. Overexpression of HOXA13 promoted CRC metastasis whereas downregulation of HOXA13 suppressed CRC metastasis. Mechanistically, HOXA13 facilitated CRC metastasis by transactivating ATP-citrate lyase (ACLY) and insulin-like growth factor 1 receptor (IGF1R). Knockdown of ACLY and IGFIR inhibited HOXA13-medicated CRC metastasis, whereas ectopic overexpression of ACLY and IGFIR rescued the decreased CRC metastasis induced by HOXA13 knockdown. Furthermore, Insulin-like growth factor 1 (IGF1), the ligand of IGF1R, upregulated HOXA13 expression through the PI3K/AKT/HIF1α pathway. Knockdown of HOXA13 decreased IGF1-mediated CRC metastasis. In addition, the combined treatment of ACLY inhibitor ETC-1002 and IGF1R inhibitor Linsitinib dramatically suppressed HOXA13-mediated CRC metastasis. In conclusion, HOXA13 is a prognostic biomarker in CRC patients. Targeting the IGF1-HOXA13-IGF1R positive feedback loop may provide a potential therapeutic strategy for the treatment of HOXA13-driven CRC metastasis.

scholarly journals Targeting the Metabolic Adaptation of Metastatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1641
Author(s):  
Josep Tarragó-Celada ◽  
Marta Cascante
Keyword(s):  
Colorectal Cancer ◽  
Cancer Metastasis ◽  
Metastatic Cancer ◽  
Breast Cancer Metastasis ◽  
Metabolic Inhibitors ◽  
Current Status ◽  
Metabolic Adaptation ◽  
Metastatic Cells ◽  
Colorectal Cancer Metastasis ◽  
Metastatic Process

Metabolic adaptation is emerging as an important hallmark of cancer and metastasis. In the last decade, increasing evidence has shown the importance of metabolic alterations underlying the metastatic process, especially in breast cancer metastasis but also in colorectal cancer metastasis. Being the main cause of cancer-related deaths, it is of great importance to developing new therapeutic strategies that specifically target metastatic cells. In this regard, targeting metabolic pathways of metastatic cells is one of the more promising windows for new therapies of metastatic colorectal cancer, where still there are no approved inhibitors against metabolic targets. In this study, we review the recent advances in the field of metabolic adaptation of cancer metastasis, focusing our attention on colorectal cancer. In addition, we also review the current status of metabolic inhibitors for cancer treatment.

scholarly journals Cell Budding from Normal Appearing Epithelia: A Predictor of Colorectal Cancer Metastasis?

2013 ◽  
Vol 9 (1) ◽  
pp. 119-133 ◽  
Author(s):  
Bin Jiang ◽  
Jeffrey Mason ◽  
Anahid Jewett ◽  
Jun Qian ◽  
Yijiang Ding ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Metastasis ◽  
Colorectal Cancer Metastasis

Colorectal Cancer Metastasis: The DNA Repair Inhibitor Dbait Increases Sensitivity to Hyperthermia and Improves Efficacy of Radiofrequency Ablation

Radiology ◽  
2014 ◽  
Vol 270 (3) ◽  
pp. 736-746 ◽  
Author(s):  
Flavien Devun ◽  
Julian Biau ◽  
Michel Huerre ◽  
Amélie Croset ◽  
Jian-Sheng Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Repair ◽  
Radiofrequency Ablation ◽  
Cancer Metastasis ◽  
Colorectal Cancer Metastasis ◽  
Dna Repair Inhibitor
Sign in / Sign up

Export Citation Format

Share Document